Combining multiple immune checkpoint inhibitors is another strategy frequently employed to potentiate the anti-tumor immune response in patients with low levels of PD-L1 expression or who are resistant to PD-1 pathway blockade [45–49]. The gene discussed is CD274; the disease is neoplasm.